10 facts from the January 2016 CRISPR patent landscape

Our quarterly CRISPR patent landscape is now available. For this first release in 2016, we haveĀ  included the latest business and technology developments, such as licensing deals information and a fully revisited breakdown of the functional and technical claim coverage. Our genomics expert Dr. Fabien Palazzoli has identified 489 CRISPR patent families out from worlwide patent registers, and systematically reviewed them down to individual claim wording to classify them into our unique, worldwide, independent CRISPR patent database.

In the meanwhile, facts and opinion papers around the Broad-Berkeley USPTO patent interference have been overloading our news monitoring capacity in the past 4 weeks… but that’s just about 2 pioneering families in the whole landscape. Here are 10 new facts out of the latest IPStudies CRISPR patent analytics – 489 CRISPR patent families as of January 2016:

  1. The number of published CRISPR patent families has been multiplied by 5 in 18 months.
  2. An increasing diversity of CRISPR actors are developing IP collaborations.
  3. More than 20 CRISPR patents have now been fast-tracked and granted at the USPTO.
  4. 10 actors now have more built a portfolio of more than 10 published patent families in the CRISPR patent landscape.
  5. Near 20% of the patent landscape publications have claims covering one or another variant of the CRISPR-Cas system as possible further specialized improvements and/or design arounds of the core technology.
  6. More than one third of the CRISPR patent landscape publications address therapeutic applications.
  7. After initial R&D positioning on the CRISPR-Cas system development in the pioneering landscape, several players are now focusing their IP on gene-specific gRNA.
  8. More than 80% of the CRISPR landscape address gene editing.
  9. Feng Zhang is the top 1 inventor in the CRISPR patent database with 36 families, while Jennifer Doudna is named on 10 families.
  10. The Chinese landscape is developing on its own, with 134 Chinese priority filings, but only 3 PCT extensions and 1 US filing registered so far.

Last but not least, we will be attending the Genome Editing conference and IP seminar in Brussels next week and we look forward to this unique opportunity to discuss more about the fast developing IP landscape – hope to see you there!

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.